ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-DLL3 Antibody-drug Conjugate IDE849

Also written as “IDE849” and “SHR-4849”.

In Jiangsu HengRui Medicine’s pipeline, DLL3 ADC. Its studies are mostly in Small Cell Lung Carcinoma, led by 2 companies.

Furthest: phase 2, since Sep 11, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
IDEAYA Biosciencesits history only11 open or runningphase 2since Sep 11, 2025Sep 11, 2025Jul 2029phase 2 · NCT07174583
Jiangsu HengRui Medicineits history only11 open or runningphase 1since May 30, 2024May 30, 2024Dec 2026phase 1 · NCT06443489
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-4849, phase 2, as of Jul 31, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 30, 2024First study: phase 1 study in Advanced Solid TumorsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06443489 · 80 planned · China
  2. Sep 11, 2025IDEAYA Biosciences’ first study: phase 2 study in Small Cell Lung CarcinomaNew to IDEAYA BiosciencesIDEAYA Biosciences · NCT07174583 · 262 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 1 study in Advanced Solid TumorsJiangsu HengRui Medicine · NCT06443489
  2. Jul 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaIDEAYA Biosciences · NCT07174583

TargetBeta

“DLL3 ADC”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) conjugated, via a cleavable linker, to a DNA topoisomerase I inhibitor (TOP1i), with potential antineoplastic activ…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) ”NCIt, by rule

Other programs on DLL3

ProgramCompanyFurthest phaseStudies
tarlatamabruleAmgenphase 313
AlveltamigruleSuzhou Zelgen Biopharmaceuticalsphase 311
obrixtamigBoehringer Ingelheimphase 311
Zocilurtatug PelitecanruleZai Labphase 36
Anti-DLL3 Antibody-drug Conjugate BL-M14D1Sichuan Biokin Pharmaceuticalphase 34
gocatamigMerckphase 34
Autologous Anti-DLL3 CAR-T Cells DJI136Novartisphase 22
SHR-7787Jiangsu HengRui Medicinephase 21
Anti-DLL3 Antibody-drug Conjugate FZ-AD005ruleShanghai Fudan-Zhangjiang Bio-Pharmaceuticalphase 12
clesitamigHoffmann-La Rochephase 12
Actinium Ac 225-ABD147ruleabdera-therapeutics-incphase 11
Indium In 111-ETN029Novartisphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07174583Small Cell Lung Carcinoma · United States2RecruitingIDEAYA BiosciencesJul 2029262
NCT06443489Advanced Solid Tumors · China1RecruitingJiangsu HengRui MedicineDec 202680

How it is read

Names in the registry

  • “IDE849”, 1 entry
  • “SHR-4849”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.